{"id":"W2261580129","doi":"10.1200/jco.2015.33.7_suppl.295","title":"Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Docetaxel; Medicine; Ramucirumab; Taxane; Metastatic Urothelial Carcinoma; Internal medicine; Clinical endpoint; Paclitaxel; Oncology; Regimen; Interim analysis; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Chemotherapy regimen; Concomitant; Progression-free survival; Chemotherapy; Urology; Clinical trial; Cancer; Breast cancer; Bladder cancer; Urothelial carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007605553,0.002285269,0.003227569,0.0005717149,0.0005092368,0.00135915,0.001052682,0.001821449,0.006399477],"category_scores_gemma":[0.006717814,0.0009147427,0.003523007,0.0003868111,0.000993176,0.001200209,0.0005674033,0.003279948,0.001344494],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009413007,"about_ca_system_score_gemma":0.001798727,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004688513,"about_ca_topic_score_gemma":0.000815767,"domain_scores_codex":[0.9967312,0.002098689,0.0001681757,0.0003000561,0.0002173534,0.0004846677],"domain_scores_gemma":[0.9957528,0.001680052,0.0009396768,0.0005117416,0.0002308888,0.000884861],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9780919,0.007341767,0.001378257,0.0001343583,0.0009202431,0.00006114411,0.00003970589,0.001010458,0.001788751,0.00007015229,0.001026397,0.008137025],"study_design_scores_gemma":[0.705503,0.2801039,0.007293662,0.00002864835,0.00161961,0.0001139193,0.00002650864,0.001724474,0.001764994,0.0003741127,0.001411641,0.00003557594],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9756108,0.002010734,0.002267138,0.0006461384,0.0005601175,0.00977174,0.005638685,0.00023801,0.003256607],"genre_scores_gemma":[0.9734088,0.000643166,0.003872856,0.001108382,0.0003266201,0.01112327,0.006243504,0.0000752077,0.003198322],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007605553,"threshold_uncertainty_score":0.04022247,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2496123628766848,"score_gpt":0.5155956843028914,"score_spread":0.2659833214262065,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}